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BACKGROUND: Thymidine phosphorylase (TP) is often overexpressed in tumours and has a role in tumour aggressiveness and
angiogenesis. Here, we determined whether TP increased tumour invasion and whether TP-expressing cancer cells stimulated
angiogenesis.
METHODS: Angiogenesis was studied by exposing endothelial cells (HUVECs) to conditioned medium (CM) derived from cancer cells
with high (Colo320TP1¼CT-CM, RT112/TP¼RT-CM) and no TP expression after which migration (wound-healing-assay) and
invasion (transwell-assay) were determined. The involvement of several angiogenic factors were examined by RT–PCR, ELISA and
blocking antibodies.
RESULTS: Tumour invasion was not dependent on intrinsic TP expression. The CT-CM and RT-CM stimulated HUVEC-migration and
invasion by about 15 and 40%, respectively. Inhibition by 10 mM TPI and 100 mM L-dR, blocked migration and reduced the invasion by
50–70%. Thymidine phosphorylase activity in HUVECs was increased by CT-CM. Reverse transcription-polymerase chain reaction
revealed a higher mRNA expression of bFGF (Colo320TP1), IL-8 (RT112/TP) and TNF-a, but not VEGF. Blocking antibodies
targeting these factors decreased the migration and invasion that was induced by the CT-CM and RT-CM, except for IL-8 in CT-CM
and bFGF in RT-CM.
CONCLUSION: In our cell line panels, TP did not increase the tumour invasion, but stimulated the migration and invasion of HUVECs by
two different mechanisms. Hence, TP targeting seems to provide a potential additional strategy in the field of anti-angiogenic therapy.
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The platelet-derived endothelial cell growth factor (PD-ECGF) is
also known as thymidine phosphorylase (TP). Numerous immuno-
histochemical and TP-activity studies have shown an increased TP
expression and activity in a wide-range of solid tumours,
compared with normal healthy tissues (Ackland and Peters,
1999; De Bruin et al, 2006; Bronckaers et al, 2009a, b). A high TP
expression in these tumour sites has clearly been related to a high-
microvessel density, the induction of metastasis and a poor
prognosis for the patient (Kidd et al, 2005; Nakayama et al, 2005;
Hayashi et al, 2008). The location of TP expression varies between
tumour type and grade and has been reported to be highly
expressed in tumour cells (O’Brien et al, 1996), the invasive part or
the tumour (Kubota et al, 1997; Yoshikawa et al, 1999; Hayashi
et al, 2008) or in the tumour stromal cells (Nagaoka et al, 1998;
Sakamoto et al, 1999; Liakakos et al, 2006; Ruckha¨berle et al,
2010). From these studies about TP, we conclude that TP is
involved in two different, but overlapping actions. First, it is
related to a higher invasive property and metastatic potential of the
cancer cells (De Bruin et al, 2006; Yu et al, 2008; Bronckaers et al,
2009a, b). Second, it is related to an increased angiogenesis. The
mechanisms underlying TP aggressiveness in cancer cells are
possibly by comparable cellular events as for that of angiogenesis.
However, the exact molecular mechanisms behind these actions
remain unclear.
Thymidine phosphorylase catalyses the reaction of thymidine
(TdR) to deoxyribose-1-phosphate (dR-1-P) and thymine. From
this reaction, deoxyribose (dR) can be formed (Bijnsdorp et al,
2010a). It is believed that dR has a role in the angiogenic effects of
TP (Hotchkiss et al, 2003), as dR can be secreted from the cells
(Bijnsdorp et al, 2010a). Deoxyribose has shown angiogenic
properties in various in vitro and in vivo studies (Stevenson
et al, 1998; Hotchkiss et al, 2003; Sengupta et al, 2003). Exposure of
endothelial cells to dR and TP stimulated both the migration and
invasion, and activated the focal adhesion kinase (FAK) and
p70/S6k (Hotchkiss et al, 2003; Seeliger et al, 2004). Focal adhesion
kinase has an important role in the invasion and migration of cells
and also in cell death regulation (McLean et al, 2005). P70/S6k is
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the important downstream kinase of mTOR, regulating cell
proliferation, metabolism and also angiogenesis (Chiang and
Abraham, 2007). In addition to angiogenesis, the mTOR-FAK
signalling pathway also seems to be involved in the invasive
potential of TP in cancer cells. Besides sugars that are produced by
TP conversion of TdR, other mechanisms are possibly involved as
well. A high TP expression has been related to an increased
secretion of angiogenic factors, such as IL-8 and bFGF (Brown
et al, 2000). Moreover, TP is often co-expressed with the important
angiogenic factor vascular endothelial growth factor (VEGF)
(Sivridis et al, 2002). However, whether TP can regulate VEGF is
unclear.
To reduce tumour aggressiveness and angiogenesis, TP inhibi-
tors have been synthesised. The TPI is a very potent and specific
inhibitor of TP and does not inhibit uridine phosphorylase (UP)
(Fukushima et al, 2000). Uridine phosphorylase can also break
down thymidine in cancer cells (Temmink et al, 2007). Another
possibility to inhibit one of the downstream biological actions of
TP is by addition of L-deoxyribose, a stereoisomer of dR (Nakajima
et al, 2004). Although L-dR is often used to study TP functioning,
dR is not the only product that is responsible for the pro-
angiogenic activity of TP (Brown and Bicknell, 1998; Brown et al,
2000). Therefore, the use of specific TP inhibitors are evaluated for
their anti-angiogenic potential in cancer cells.
It is not exactly known how cancer cells with a high TP
expression can stimulate endothelial cells to form new blood
vessels. The aim of the present study was to evaluate the role of TP
in cancer cells on the proliferation, migration and invasion of
endothelial cells and to identify several potential angiogenic factors
in their involvement in these process. Therefore, we used
conditioned medium from TP-expressing cells to determine
whether tumour cells secrete molecules that stimulate angiogen-
esis. As the TP expression in cancer cells also increase their
aggressiveness, we also determined the level of invasion and
intracellular signalling of colon cancer and bladder cancer cell
lines, with and without TP expression.
MATERIALS AND METHODS
Cell lines
Human colon cancer cell lines Colo320, Colo320TP1
(TP-transfected; De Bruin et al, 2003), RT112 and RT112/TP
(TP-transfected; Brown et al, 2000) were cultured as monolayers in
DMEM, supplemented with 20mM Hepes and 10% fetal calf serum
(FCS). Human umbilical vein endothelial cells (HUVECs) were
isolated from human umbilical cords and were cultured in M199
medium, supplemented with 10% FCS (PAA laboratory GmbH,
Co¨lbe, Germany), 10% human serum (HS) and ECGF. All cells
were maintained in a humidified 5% CO2 atmosphere at 371C. For
all experiments in which HUVECs were used, at least three
different isolations (e.g. donors) were examined for their
(angiogenic) response.
TP enzymatic activity
Thymidine phosphorylase enzymatic activity was performed by
HPLC measurement of TdR conversion to thymine as described
previously (De Bruin et al, 2004). In brief, HUVECs were exposed
to the CM with 100mM TdR for 6 h, after which the medium was
collected. For each added TdR concentration in the CM, a t¼ 0
timepoint was collected and TdR levels were measured in these
samples for correction. In addition, in the CM, the TP activity was
measured after 24 and 48 h incubation with 100 mM TdR incubation
at 371C. Subsequently, trichloroacetic acid (TCA) was added for
20min and samples were centrifuged at 14 000 g at 41C for 10min.
The supernatant was transferred to a new vial, and the pH was
neutralised. Thymidine, deoxyribose and thymine were measured
by HPLC analysis for nucleosides with UV detection as described
previously (Laurensse et al, 1988).
Concentrating conditioned medium
Cancer cells were seeded (2–2.5 106 cells/T75 culture flask
(Greiner Bio-One, Alphen a/d Rijn, The Netherlands) in exactly
15ml medium. After 3 days of normal growth, the medium was
collected and filtered through a 0.22mm filter to remove any
floating cells. Subsequently, the medium was concentrated 20
using Amicon Ultra 15 Centrifugal filters (Milipore, Billerica, MA,
USA). This concentrated medium was stored at 201C in aliquots.
For each experiment, the concentrated medium was thawed and
diluted 1 : 20 in HUVEC-medium. From this diluted medium, the
conditioned medium (CM) is referred as C-CM (Colo320), CT-CM
(Colo320 TP1), R-CM (RT112) and RT-CM (RT112/TP).
Migration assay
Human umbilical vein endothelial cell migration was determined
using the wound healing assay as described previously (Bijman
et al, 2006; Bijnsdorp et al, 2010b). Human umbilical vein
endothelial cells were seeded (100 000 cells per well) in duplicates
in 1% gelatin coated wells of a 24 wells plate (Corning, Schiphol,
The Netherland). Cells were grown till confluence and a scratch
wound was applied in two perpendicular directions with a sterile
pipet tip. Subsequently, cells were washed two times with HBSS
and cells were exposed to the various conditioned media, diluted
in HUVEC-medium with 5% FCS and 5% HS. When blocking
antibodies were used, the medium was 30min pre-incubated in the
diluted conditioned medium. Wounds were captured at  2.5
magnification with a microscope (TCS 4D, Leica, Jena, Germany),
and Q500MC software (Leica) at time points 0, 3 and 6 h. At all
indicated time points, the wound width was measured in four areas
and compared with the initial width at the 0 h time point and were
corrected for the negative control (set at 0%).
Invasion assay
The invasion assay was carried out using transwell chambers with
a fluorescence-blocking 8 mm pore filter insert (#35–1152; HTS
Fluoroblock Insert, Falcon, Becton Dickinson Labware, Bedford,
MA, USA) (Bijman et al, 2006). The insert was coated overnight at
room temperature (RT) with 100 ml matrigel (50 ngml1 in PBS;
Sigma-Aldrich Chemicals, Zwijndrecht, The Netherlands). For
HUVEC invasion, the bottom compartment was coated with 1%
gelatin. Cells (50 000/insert) were seeded in medium with 1% FCS
and 1% HS without ECGF. In the bottom compartment, the CM
diluted in HUVEC-medium with 1% FCS and 1% HS was added.
Human umbilical vein endothelial cells were allowed to invade for
8 h. The level of invasion was set relative to the positive control
and normalised to the negative control. Cancer cells (20 0000/
insert) were seeded in serum free medium. In the bottom
compartment, medium with 10% serum was added as chemo-
attractant. Cells were allowed to invade for 18 h. For both HUVECs
and cancer cells, 5 mM calcein-AM was added 30min before
analysis to the lower compartment and fluorescently labelled cells
were counted.
Endothelial cells proliferation
At 24 h after seeding HUVECs (100 000 cells/T25 flask (Greiner
Bio-One), cells were exposed to CM diluted in HUVEC medium
containing 5% FCS and 5% HS. Cell numbers were counted after
3 and 6 days exposure using a counting chamber (Bu¨rker-Tu¨rk,
Paul Marienfeld GmbH & Co. KG, Lauda-Ko¨nigshofen, Germany).
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Western blotting
Cells were exposed to various conditions, as indicated. After
exposure, cells were washed twice with ice-cold PBS and lysed in
lysis buffer (Cell Signaling Technology Inc., Danvers, MA, USA).
Cell lysates were scraped, transferred into a vial and centrifuged at
11 000 g at 41C for 10min. Supernatants were transferred to a new
vial and protein amounts were determined by the Bio-Rad assay,
according to the manufacturer’s instruction (Bio-Rad Laboratories,
Veenendaal, The Netherlands). From each condition, 30 mg of
protein was separated on a 8–12% SDS–PAGE and electroblotted
onto polyvinylidenedifluoride (PVDF) membranes (Millipore
Immobilon –FL PVDF, 0.45mm). Subsequently, the membranes
were blocked for 1 h at room temperature (RT) in Odyssey
blocking buffer (Odyssey blocking buffer #927–40003, Westburg,
Leusden, The Netherlands) and incubated overnight at 41C with
the primary antibodies (Anti-focal adhesion kinase, anti-Akt,
anti-MAPK, anti-p70/S6k antibodies) were purchased from Cell
Signaling Technology Inc., dilution 1 : 1000–10 000 in Odyssey
blocking buffer 1 : 1 diluted with PBS-T (PBS with 0.05% Tween-20).
The membrane was washed five times in PBS-T and incubated
with the secondary antibody (1 : 10 000 goat-a-mouse-IRDye
(800CW; #926–32210 and 680; #926–32220) or goat-a-rabbit-
IRDye (800CW; 926–32211 and 680; #926–32221), Westburg) for
1 h at RT in the dark. After incubation, the membrane was washed
in PBS-T and followed by 5min washing in PBS without Tween-20
to decrease the background signal. Subsequently, the bands were
scanned using an Odyssey Infrared Imager (Westburg), 84 mm
resolution, 0mm offset and with high quality (Mathews et al,
2009).
RT–PCR
Reverse transcription-polymerase chain reaction analysis of the
angiogenic factors VEGF-A, bFGF, PLGF, TNF-a and IL-8 was
performed as described previously. (Thijssen et al, 2004, 2008)
In brief, Colo320, Colo320 TP1, RT112 and RT112/TP cells were
cultured for 3 days, after which cells were collected and RNA was
isolated. Targets were normalised to HPRT.
VEGF, IL-8 and TNF-a detection
Vascular endothelial growth factor secretion was determined using
a Quantikine human VEGF immunoassay ELISA (# DVE00; R&D
systems Inc., Minneapolis, MN, USA), IL-8 by a human IL-8 ELISA
kit (Becton Dickinson, Breda, The Netherlands) and TNF-a
Sanquin PeliKine human TNF-a ELISA kit (#M1920). The ELISAs
were performed according to manufacturer’s instructions. In brief,
concentrated medium was examined undiluted or diluted 20
and 200 . Subsequently, VEGF, IL-8 and TNF-a concentrations
were determined and calculated in relation to the calibration curve.
Statistical analysis
For calculating significant differences between the parental and the
transfected cells or between treated and untreated samples, the
two-tailed paired Student’s t-test was used. The values were
considered significantly different when Po0.05.
RESULTS
The role of TP in cancer cell invasion
To determine whether TP expression in cancer cells results in
an increased aggressiveness, Colo320, RT112 cells and their
TP-transfected variants were examined on their invasion capacity.
Colo320 and Colo320 TP1 cells hardly invaded, while RT112 and
RT112/TP cells had a high invasion capacity (Figure 1A). Colo320
and RT112 had no TP activity, while their transfected variants had
comparable TP activity (Figure 1B). There was no relation between
the level of intrinsic TP expression and level of invasion.
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Furthermore, the invasive potential was not increased by
stimulating TP activity with TdR or by the main secreted product
of this reaction dR (Figure 1A). The TP inhibitor, TPI (10 mM),
did not affect the invasion of these cancer cell lines.
Taken together, these data suggest that intrinsic TP expression
in RT112/TP and Colo320 TP1 cancer cells does not affect their
invasive characteristic.
Expression levels of phospho-FAK and phospho-p70/S6k
were lower in TP-expressing cells
To determine whether differences in invasion between the two cell
types were related to a different expression level of the FAK-Akt-
p70/S6k pathway, the expression and phosphorylation levels were
determined by western blotting (Figure 1C). All cell lines
constitutively expressed FAK and Akt and p70/S6k. Phosphoryla-
tion levels of FAK and Akt were higher in RT112 and RT112/TP.
Interestingly, compared with the parental cell lines, phosphory-
lated-FAK and phosphorylated-p70/S6k were observed to be lower
in the TP-transfected variants, although the invasion levels were
not different between the cell lines. Taken together, the
phosphorylation levels of the kinases in these cell lines were
different when TP was highly expressed, which might be related to
the difference in their behaviour.
CM from cancer cells with a high TP expression does not
stimulate endothelial cell proliferation
To determine the angiogenic response of endothelial cells, various
angiogenic properties were studied using endothelial cells,
including proliferation, migration and invasion. As angiogenesis
is a process that involves endothelial cells, we examined the
angiogenic responses in endothelial cells derived from human
umbilical veins (HUVECs). We prepared conditioned medium
from the cancer cells with high TP and no TP expression and
stimulated HUVECs with this medium and subsequently examined
the angiogenic responses. To determine whether cancer cells with a
high TP expression can stimulate HUVEC proliferation, HUVECs
were exposed to the CM of the cancer cells and HUVECs were
counted after 3 and 6 days of culture. Under these used conditions
(5% of both FCS and HS), the CM did not stimulate the
proliferation of the HUVECs at all (data not shown). This indicates
that cancer cells did not secrete products that directly stimulated
HUVEC proliferation.
CM from cancer cells with a high TP expression can
stimulate endothelial cell migration
To determine whether the CM derived from cancer cells with a
high TP expression could stimulate the migration of the HUVECs,
the wound-healing assay was performed. We used experimental
conditions comparable with the proliferation assay, because
under these conditions the HUVECs were viable, but do not
proliferate. The CM derived from TP-expressing cells (RT-CM
and CT-CM) stimulated the migration by about 15–20%,
respectively. The CM derived from non-TP-expressing cells
(C-CM and R-CM) did not significantly increase the migration
of the HUVECs (Figure 2A). Addition of 10 mM TPI and 100mM
L-dR to RT-CM and CT-CM reduced HUVEC migration
back to control levels (Figure 2B), while these inhibitors did
not affect the migration of the controls or the C-CM and R-CM
(data not shown).
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CM from cancer cells with a high TP expression stimulate
endothelial cell invasion
To determine whether the CM derived from cells with a high TP
expression can increase the invasion capacity of the HUVECs, the
transwell invasion assay was performed. In agreement with the
wound-healing assay, the CM derived from cells with a high TP
expression attracted endothelial cells by about 40–45%
(Figure 2C). The CM from cells with no TP expression did not
significantly increase the invasion of HUVECs (Figure 2C). The
TPI (10mM) reduced the invasion that was induced by RT-CM and
CT-CM by almost 50% (Figure 2D), which may be related to the
addition of TPI to the conditioned medium and not to the cancer
cells during medium collection. The L-dR inhibited the RT-CM
and CT-CM induced invasion by almost 90%. The TPI and L-dR
did not inhibit or stimulate the invasion of the controls (data not
shown).
Activation of p70/S6k expression levels of endothelial cells
The differences in migration and invasion between HUVECs
stimulated by the CM from TP-expressing cells and non-TP-
expressing cells may be related to the activation of different
intracellular signalling pathways. To study this, a western blot was
performed determining expression levels of (phosphorylated)
FAK, Akt and p70/S6k. These kinases were previously reported
to be involved in TP-mediated cell migration and invasion
(Figure 3A). Upon 2 h stimulation of endothelial cells with the
control medium, phosphorylated levels of mTOR were decreased.
After 6 h, these levels were back to control levels and phosphory-
lation levels of the downstream p70/S6k were decreased. The CM
resulted in increased phosphorylation levels of mTOR after 2 h.
After 6 h, exposure to C-CM, CT-CM and R-CM resulted in
increased p-p70/S6k phosphorylation levels. Phosphorylated
levels of mTOR and FAK were not changed at all. This indicates
that these signalling molecules were probably not involved in
the migration or invasion induced by the CM derived from
TP-expressing cells.
TP enzymatic activity in HUVECs was increased by the CM
from Colo320 TP1 cells
To determine whether the effect of the CM was related to an
induction of TP expression of the HUVECs, TP enzymatic
activity was determined. The C-CM and R-CM did not increase
TP activity. CT-CM increased the TP activity of the HUVECs,
compared with the C-CM (Figure 3B). However, RT-CM only
slightly increased the TP activity of the HUVECs. As TP can be
secreted from the cells and thus be present in the conditioned
medium, the TP activity was evaluated in the CM. Thymidine
phosphorylase activity in this CM was lower than 10 pmol/million
seeded cells h1 in all the conditioned media, thus the TP present
in this CM could be neglected. The increase in invasion and
migration induced by the CT-CM is possibly related to the
increased TP expression of the HUVECs, and is an explanation
why TPI (partially) inhibited the migration and invasion capacity
of these cells.
Increased expression of IL-8, TNF-a and bFGF in
TP-expressing cells
The influence of the TP-expressing cells on the increased
migration and invasion of the HUVECs can be related to an
increased expression and secretion of angiogenic factors. There-
fore, we examined the mRNA expression levels of various
important angiogenic factors in Colo320, Colo320 TP1, RT112
and RT112/TP cells (Figure 4A) (Thijssen et al, 2004). The most
prominent difference between RT112 and RT112/TP cells was the
expression of IL-8, which was much higher in RT112/TP cells
(Figure 4B). However, in both Colo320 and Colo320 TP1 cells, IL-8
was not expressed. Other factors that were significantly increased
include TNF-a, and bFGF, which were about two- to six-fold
increased (Figure 4B). The differences in mRNA expression levels
between Colo320 and Colo320 TP1 cells were less compared with
the differences in RT112 and RT112/TP cells. Vascular endothelial
growth factor was not differentially expressed between the parental
and transfected cell lines. TNF-a was expressed to a significant
lower extent in Colo320 TP1 compared with Colo320 cells, and was
higher expressed in RT112/TP than in RT112 cells. Taken together,
various angiogenic factors were differentially expressed in
TP-expressing cells, compared with non-TP-expressing cells,
indicating a role for TP in modulating the expression of these
angiogenic factors. The expression of these angiogenic factors were
cell-type dependent, indicating that TP is not the only factor that is
involved.
To examine whether angiogenic factors were secreted, we
selected VEGF, IL-8 and TNF-a for further investigation, as they
are often implicated in stimulation of angiogenesis. TNF-a was
hardly detectable in the conditioned medium or in the medium
with ECGF (data not shown). Vascular endothelial growth factor
was secreted at higher levels in C-CM than in CT-CM. The R-CM
had higher levels of VEGF than the C-CM, but the levels were not
different in the transfected variant (Figure 4C). In RT-CM, the IL-8
levels were much higher, compared with the R-CM, which is in
agreement with the mRNA expression levels (Figure 4C). In both
C-CM and CT-CM, IL-8 was not detectable.
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Inhibition of IL-8, bFGF, TNF-a and VEGF reduced the
migration and invasion
To determine whether TNF-a, VEGF, IL-8 and bFGF were related
to the increased migration and invasion of the HUVECs, blocking
antibodies were used that specifically inhibit their angiogenic
modulation (Figure 4D). The induced migration by RT-CM was
completely inhibited by blocking TNF-a, VEGF, IL-8 and bFGF.
The induced migration and invasion by CT-CM were completely
blocked by antibodies against TNF-a, VEGF and bFGF, but not by
that against IL-8. This is in agreement with the lack of IL-8 mRNA
expression and absence of protein secretion. Taken together,
several angiogenic factors were involved in the TP-mediated
modulation of the migration and invasion of HUVECs. The
blocking antibodies against VEGF, IL-8 and bFGF inhibited the
migration and invasion of R-CM to some extent, although to a
lesser extent than that of RT-CM (data not shown). C-CM-induced
migration and invasion were not inhibited by any of the tested
blocking antibodies. This indicates that IL-8, bFGF and possibly
TNF-a and VEGF were involved in TP-induced migration and
invasion.
DISCUSSION
The present data show that conditioned medium derived from cells
with a high-TP expression, stimulate the migratory and invasive
capacity of endothelial cells, by activating two different mechan-
isms. The increased TP expression in cancer cells stimulate the
secretion of several angiogenic factors and also Colo320 TP1
medium increased the TP activity in HUVECs. The secretion of
angiogenic factors was different between the two cell types. In
cancer cells, a high TP expression (e.g., cancer cells transfected
with the TP gene) was not related to an increased invasion of the
cells themselves, indicating that the invasive potential in our cell
lines was not related to TP expression.
Limited studies related TP to angiogenesis (De Bruin et al, 2006;
Bronckaers et al, 2009a, b). From these studies, it was concluded
that TP expression and activity was clearly related to the presence
of angiogenesis. However, the mechanism behind angiogenesis
that is induced by TP-expressing cells is not completely under-
stood. To study the angiogenic role of TP, exogenous TP or dR
have been used (Brown et al, 2000; Hotchkiss et al, 2003; Seeliger
et al, 2004). However, other factors may also be involved (Brown
et al, 2000). Therefore, we used conditioned medium from
TP-expressing cells to determine whether tumour cells secrete
pro-angiogenic molecules. TP-expressing cells indeed secreted
angiogenic factors (IL-8, bFGF) that stimulated endothelial cell
migration and invasion, but not proliferation. The secretion of the
angiogenic factors VEGF and IL-8 has been demonstrated before in
RT112/TP cells by Brown et al (2000). Our data are in agreement
with their data, indicating that IL-8 has a role in TP-mediated
migration and invasion in this cell line. However, we did not find
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an increased VEGF secretion by RT112/TP cells, possibly because
of the lower glucose levels (5.5mM instead of standard 25mM in
culturing conditions) that Brown et al (2000) used in their study.
The limited or even absent effect of the secreted VEGF in
stimulating migration and invasion in our study is in agreement
with observations from Hotchkiss, who reported that TP and
VEGF are independent expressors (Hotchkiss et al, 2003). In
addition to IL-8, we demonstrate a possible role of bFGF and
TNF-a in TP-mediated stimulation of migration and invasion. The
bFGF and TNF-a are well documented angiogenic growth factors
that stimulate endothelial cell migration (Yoshida et al, 1997;
Rosenkilde and Schwartz, 2004; Wang and Lin, 2008; Szekanecz
et al, 2009). Many angiogenic factors enhance each other’s effect to
stimulate angiogenesis (Yoshida et al, 1997; La´za´r-Molna´r et al,
2000). However, inhibition of only one of these factors (even when
not upregulated) can already result in a complete inhibition of the
angiogenic effects, as inhibition of one of these factors (such as
VEGF, which was not upregulated) resulted in a complete
inhibition of migration and invasion. Therefore, a combination
of these angiogenic factors could still be responsible for the
angiogenic effect of TP. Future experiments should elucidate to
which extent TPI affects the secretion of angiogenic factors by the
tumour cells.
To study the role of TP in angiogenesis, L-dR is often used
(Nakajima et al, 2009), including other inhibitors of TP (Liekens
et al, 2007; Bronckaers et al, 2009a, b). Enzymatic inhibition of TP,
inhibited the induction of angiogenesis, indicating that the
enzymatic activity of TP in indispensable for these effects. L-dR
inhibited the migration and invasion of endothelial cells
(Uchimiya et al, 2002), which indicates that dR produced by the
cells can be one of the key factors in angiogenesis. Moreover, L-dR
inhibited the formation of focal contacts between endothelial cells
(Hotchkiss et al, 2003). In the present study, we demonstrate that
Colo320TP1 cancer cells increased the TP expression of HUVECs,
which might increase their angiogenic potential. The inhibitors
TPI and L-dR reversed these effects, indicating that TP and dR
have a role. The development of TP inhibitors such as TPI provides
potential for inhibiting migration and invasion of endothelial cells,
and can be combined with various anti-cancer agents.
The molecular pathway that is activated upon stimulation of TP
can be different between endothelial and cancer cells. In
endothelial cells, exogenously added TP and dR activate integrins,
subsequent downstream signalling pathways involving FAK and
p70/S6k and the migration and invasion of endothelial cells
(Hotchkiss et al, 2003; Seeliger et al, 2004; Pula et al, 2010). FAK is
a non-receptor tyrosine kinase that has a role in cell migration and
cell death (McLean et al, 2005). However, conditioned medium
only activated p70S6k, but not FAK, while the effects were not
different between TP-expressing cells and the non-TP-expressing
cells. Therefore, this molecular pathway may not be involved in
TP-dependent migration and invasion. Apparently, exogenous TP
or dR inflicts other cellular responses than cells with intrinsically
high TP expression or stimulating endothelial cells with condi-
tioned medium from TP-expressing cancer cells.
Thymidine phosphorylase expression in cancer cells might also
influence their aggressiveness (Nakajima et al, 2004, 2006). Our
data show that intrinsic TP expression of Colo320, Colo320TP1,
RT112 and RT112/TP cancer cells did not increase the invasiveness
of caner cells themselves. Yu et al (2008) reported that gastric
cancer cells had a higher invasive potential and activated FAK and
p70/S6k phosphorylation levels. The difference between their data
and our data is possibly related to the different tumour types.
Other cell types may respond different to their TP expression,
possibly because of different genetic profile (De Bruin et al, 2006;
Bronckaers et al, 2009a, b). Possibly, TP is not a key factor in the
increased invasive potential of colorectal and bladder cancer cells,
but other factors need to be differentially expressed as well. Future
studies should investigate these co-factors important for the
invasive potential of cancer cells with a high TP expression.
In conclusion, TP can stimulate endothelial cell migration and
invasion, possibly by inducing the secretion of a combination of
the angiogenic factors IL-8, bFGF and TNF-a and increasing
endothelial cell TP activity. This underlines the important
potential for developing TP inhibitors as anti-angiogenesis
therapy. In addition, many anti-cancer agents can increase the
TP expression of cancer cells. Therefore, combining TP inhibitors
with these anticancer agents can have potential for targeting cancer
dually.
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